Andrew Spencer

26PUBLICATIONS
152CO-AUTHORS
Medical biotechnology diagnostics (incl. biosensors)Medical physicsGene and molecular therapyMedical microbiology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jun 08, 2026
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

|Apr 08, 2026
HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.

Elizabeth Hughes, Piers Blombery, Sushmitha Kannan

|Mar 02, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Rakesh Popat, Bradley Augustson, Paul Cannell

|Nov 08, 2025
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

Sueh-Li Lim, Cameron Wellard, Rajeev Rajagopal

|Jul 28, 2025
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.

Christina Kazzi, Ty Simpson, Miriam Wronski

|Jun 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur

Pageof 5

Frequent Collaborators

5 joint publications

Hang Quach

5 joint publications

Simon J Harrrison

4 joint publications

Phoebe J Ho

3 joint publications

Maria-Victoria Mateos